Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Lexeo Therapeutics (NASDAQ:LXEO) from a sell rating to a hold rating in a report published on Saturday morning.

A number of other research firms also recently issued reports on LXEO. Oppenheimer began coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of Lexeo Therapeutics in a research report on Monday, November 3rd. Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday. Guggenheim assumed coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Lexeo Therapeutics Stock Down 2.7%

NASDAQ LXEO traded down $0.23 during trading hours on Friday, hitting $8.19. 2,851,891 shares of the stock were exchanged, compared to its average volume of 1,457,572. The company has a market cap of $442.27 million, a price-to-earnings ratio of -3.03 and a beta of 1.75. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $11.72. The stock has a 50-day moving average of $7.23 and a 200 day moving average of $5.13.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.15. On average, equities research analysts expect that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Insider Activity at Lexeo Therapeutics

In other news, insider Tai Sandi See sold 3,888 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $34,758.72. Following the sale, the insider directly owned 65,862 shares in the company, valued at approximately $588,806.28. This represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard Nolan Townsend sold 13,133 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the sale, the chief executive officer directly owned 242,118 shares in the company, valued at $2,164,534.92. This represents a 5.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 29,091 shares of company stock valued at $232,007. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC purchased a new stake in Lexeo Therapeutics in the 2nd quarter worth approximately $60,000. Ethic Inc. purchased a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at $44,000. Affinity Asset Advisors LLC acquired a new position in shares of Lexeo Therapeutics in the first quarter worth $5,139,000. Palumbo Wealth Management LLC purchased a new stake in shares of Lexeo Therapeutics during the second quarter worth $226,000. Finally, Privium Fund Management B.V. boosted its position in Lexeo Therapeutics by 11.3% during the second quarter. Privium Fund Management B.V. now owns 178,356 shares of the company’s stock valued at $753,000 after purchasing an additional 18,158 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.